Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

901.57 -25.49 (-2.75%)
Streaming Delayed Price Updated: 10:03 AM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
News headline image
Ventyx (VTYX) Shares Soar 62.5% Overnight, Here&#39;s What&#39;s Going On With This Trending Stock ↗
Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma company for over $1 billion. 
Via Benzinga
Eli Lilly Stock Rises After Hours On UBS ‘Buy’ Call Ahead Of Oral Obesity Pill Launch — GLP-1 Battle With Novo Heats Up ↗
Via Stocktwits
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market. 
Via The Motley Fool
News headline image
Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial? ↗
Novo Nordisk has some good GLP-1 news, but is the company's failed Alzheimer's trial a long-term problem? 
Via The Motley Fool
Topics Intellectual Property
Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’ ↗
Via Stocktwits
News headline image
Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover ↗
Shares of Ventyx Biosciences launched late Tuesday on reports Eli Lilly could be nearing a $1 billion deal to buy the company. 
Via Investor's Business Daily
News headline image
The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026
As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a... 
Via MarketMinute
Topics Economy
News headline image
S&P 500 Shatters Records: Index Crosses 6,944 as Tech Giants and Healthcare Titans Lead the Charge
The S&P 500 reached a historic milestone on January 6, 2026, closing at a new all-time high of 6,944.82. This 0.6% gain on the first full trading week of the year signals a powerful continuation of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Ventyx Biosciences Stock Jumps On Reports Of Eli Lilly Buyout ↗
A deal for Ventyx could be announced imminently, the Wall Street Journal reported, citing people familiar with the matter. 
Via Stocktwits
News headline image
Eli Lilly Inks Deal With Nimbus Therapeutics To Find New Obesity Drug With AI ↗
Under the deal, Nimbus is eligible to receive up to $1.3 billion. 
Via Stocktwits
News headline image
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall
As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value? ↗
Eli Lilly offers investors safety and growth. 
Via The Motley Fool
News headline image
Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss ↗
Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide. 
Via Investor's Business Daily
News headline image
Motley Fool Money: Stock Market Naughty and Nice List ↗
There were nice companies and great CEOs in 2025, but also some duds. We discuss the stocks on each list and end by going shopping for stocks. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown? ↗
Several clinical readouts and regulatory decisions are scheduled for Eli Lilly in 2026. 
Via Stocktwits
News headline image
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗
The development comes as attention remains on Hims’ longer-term business expansion initiatives. 
Via Stocktwits
News headline image
2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Prediction: The S&P 500 $1 Trillion Club Will Double Between 2026 and 2030 ↗
Several companies could see massive gains by 2030 to join the vaunted club. 
Via The Motley Fool
Topics Stocks
News headline image
The 2026 Blueprint: Five Core Stocks to Anchor Your Portfolio in a Year of AI Realization
As we cross the threshold into 2026, the financial markets have entered a sophisticated new phase. The "AI Gold Rush" of 2024 and 2025 has matured into what analysts are calling the "Era of AI... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Should Investors Be Worried That the "Magnificent Seven" Make Up 35% of the S&P 500? ↗
At the very least, investors should be concerned. There's a way to avoid the problem, though. 
Via The Motley Fool
Topics Stocks
Top S&P500 movers in Monday's session ↗
Via Chartmill
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
News headline image
Bank of America Issues 2026 'Priced for Perfection' Warning: Why the S&P 500 Faces a High-Stakes 'Air Pocket'
As the financial world rings in 2026, a sobering forecast from one of Wall Street’s most influential institutions has sent a ripple of caution through the markets. Bank of America (NYSE: BAC) Global... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Priced for Perfection: Bank of America Issues Stark Warning on S&P 500 Valuation for 2026
As the calendar turns to 2026, the euphoria that propelled the stock market through three consecutive years of double-digit gains is facing a sobering reality check. Bank of America (NYSE: BAC) has... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever ↗
Via MarketBeat
News headline image
Eli Lilly: Strength Meets GLP‑1 Access Momentum ↗
Eli Lilly's stock remains robust at $1,080.36 amid positive market developments, strong GLP-1 access momentum, and heightened investor interest ahead of key earnings announcements. 
Via Talk Markets
News headline image
Is It Time to Dump Your Shares of Eli Lilly? ↗
Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game. 
Via The Motley Fool
News headline image
2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
4 Stocks to Buy in January That Could Join Nvidia in the $1 Trillion Club by 2030 ↗
Visa, ExxonMobil, Oracle, and Netflix have multi-year compounding potential for patient investors. 
Via The Motley Fool
Topics Artificial Intelligence
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.